In­dus­try groups cri­tique new guid­ance for Medicare drug price ne­go­ti­a­tions in 2027

The Cen­ters for Medicare & Med­ic­aid Ser­vices pro­posed a num­ber of changes to its Medicare ne­go­ti­a­tion guid­ance on Fri­day, some of which would af­fect how the next round of drug prices is ne­go­ti­at­ed un­der the In­fla­tion Re­duc­tion Act. On Mon­day, in­dus­try groups PhRMA and BIO raised new con­cerns about the guid­ance.

For prices tak­ing ef­fect in 2027, CMS will se­lect up to 15 ther­a­pies for Medicare ne­go­ti­a­tions next year. The agency is still in the mid­dle of ne­go­ti­a­tions for the first round of 10 drugs set for 2026, but said it’s look­ing for ways to make the next round more “ef­fi­cient and ef­fec­tive.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER